Clinical trial · Observational
Determining the Mechanisms of Loss of CAR T Cell Persistence
NCT05809284CI-TRIAL-00121076CARPERSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia, Adult | Adult Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.78 |
| Acute Lymphoblastic Leukemia Not Having Achieved Remission | — | UNRESOLVED | — |
| Acute Lymphoblastic Leukemia, Pediatric | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Acute Lymphoblastic Leukemia With Failed Remission | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Time to circulating CAR-T cell loss
- timeFrame
- Through study completion, until the last patient reaches 1 year post-infusion
- description
- CAR-T persistence will be measured in the central lab from blood samples.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: 1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel) 2. Written informed consent Exclusion Criteria: 1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial 2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol
References
Publications (0)
Data not yet available
No reference posted for this study.